High rate of IDH1 mutation clearance and measurable residual disease negativity in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib (AG-120) and azacitidine Meeting Abstract
| Authors: | Daigle, S. R.; Choe, S.; Quek, L.; DiNardo, C. D.; Stein, A.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Kantarjian, H. M.; Zhang, V.; Winkler, T.; Vyas, P.; Wu, B. |
| Abstract Title: | High rate of IDH1 mutation clearance and measurable residual disease negativity in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib (AG-120) and azacitidine |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577160406087 |
| DOI: | 10.1182/blood-2019-122590 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2706 -- Source: Wos |
